Beyond the Breaking News

Tools to Fight Hantavirus Show Promise Despite Limited Funding

Health News

Tools to Fight Hantavirus Show Promise Despite Limited Funding
HantavirusVirusTreatment

Researchers in Chile, Argentina, and the United States are working to develop treatments for hantavirus, a rare but deadly rodent-borne virus, despite limited funding and investment.

Tools to fight hantavirus show promise despite limited funding. Now researchers hope to continue María Inés Barría, a virologist at the Universidad San Sebastián, works at the university, in Santiago, Chile on May 20.

SANTIAGO, Chile — When a rare but deadly rodent-borne virus struck passengers on a cruise ship and seemed to be spreading, there were no treatments for those who fell ill and no vaccines to protect others. That was the case even though it wasn't a novel germ that the world had never seen before, like the virus that caused the coronavirus pandemic.

It was a hantavirus, one of a family of viruses that have been known for decades and are thought to exist around the world. Teams of researchers, including in Chile, Argentina and the United States, have long been trying to find and develop drugs and vaccines.

But because the viruses are relatively rare and don't spread easily between people, there hasn't been enough sustained investment by governments, global health groups, or drug companies to pay for the extensive safety and efficacy testing needed to make them available. Still, there have been some promising developments. Researchers on Wednesday published a hint that a drug used for an autoimmune disease may help hantavirus patients fight off the most deadly symptoms.

They and others hope the attention that the cruise ship outbreak brought to the virus — and concern that hantavirus infections could become more common as a changing climate is expected to increase contact between people and rodents — may bring new momentum to the hunt.

"I hope this situation will help us continue our research and strengthen the collaboration between healthcare workers, the community, and the necessary resources," said Dr. Fernando Tortosa of the National University of Río Negro in Patagonia, Argentina, the study's lead author. Hantaviruses usually spread when people inhale contaminated residue of rodent droppings. But there are unique species of hantavirus found in different parts of the world that have their own characteristics and can cause different symptoms.

The Andes virus, the germ behind the cruise ship outbreak, is a particular focus of researchers because it is the only hantavirus thought to be able to spread between people in some cases. And while hantavirus infections are rare, they can be extremely deadly.

"That is why it is a public health problem," said María Ines Barría, a virologist at the Universidad San Sebastián in Chile who studies hantaviruses. Three of the 13 likely cases among cruise ship passengers ended in death. Separately, in Chile, the Ministry of Health has confirmed 15 deaths and 42 cases of hantavirus so far this year. Authorities in Argentina have reported 32 deaths and 102 cases since June 2025.

In the US, 35 per cent of the hantavirus cases since tracking began in 1993 have resulted in death, according to the US Centres for Disease Control and Prevention. In Argentina, researchers are testing whether a treatment for rheumatoid arthritis might help fight hantavirus pulmonary syndrome, a severe infection caused by both the Andes virus and the Sin Nombre virus, a type of hantavirus found in North America.

The drug tocilizumab tamps down a molecule called IL-6 that triggers damaging inflammation in some autoimmune and other diseases. IL-6 also is a suspect in the inflammatory reaction to the infection, which can rapidly cause lungs to fill with fluid and fail. Four of five patients in an Argentinian hospital survived after receiving tocilizumab in addition to traditional supportive care for hantavirus pulmonary syndrome, the research team reported in The Lancet Infectious Diseases.

The report is unusual, tracking the first people to receive tocilizumab in an ongoing "compassionate use" study — meaning doctors can use it in patients they deem eligible. Another five who were deemed eligible for tocilizumab but didn't get it and instead received only standard care died. Two worsened too quickly and the hospital lacked supply for the others, the researchers reported.

The research team cautioned that the five patients who didn't receive the drug were sicker and older than those who did. Still, they said tocilizumab warrants further investigation. Barría's team, which includes Chilean scientists, researchers from the US National Institutes of Health's Rocky Mountain Laboratories and the Robert Koch Institute in Germany, is working on another approach — using cloned antibodies from hantavirus survivors to fend off infections.

The team published research in 2018 showing the approach worked in animals, but they were not able to get funding to continue with human trials, in part because resources were diverted to fight the coronavirus pandemic. Several other groups, including at the Albert Einstein College of Medicine and the Vanderbilt Center for Antibody Therapeutics, are also working on antibody treatments.

Vaccines against so-called Old World hantaviruses have been developed and used, though the World Health Organisation says there are no current licensed hantavirus vaccines. But there are new vaccines in the works, including ones aimed to fight the Andes virus.

A team lead by Jay Hooper of the US Army Medical Research Institute of Infectious Diseases, is working on a vaccine that has successfully generated antibodies against the virus in early-stage human trials, according to a study the team published in 2020. Dr. Paul Bollyky, an infectious disease doctor and researcher at Stanford Medical Center in California, said attracting and sustaining the support needed to produce vaccines and treatments is extremely difficult for rare diseases like hantavirus.

For one, labs typically don't have what Bollyky calls the necessary machinery they need to test and validate vaccines and treatments for rare infections. Also, because hantavirus outbreaks are so sporadic and unpredictable, that virus is much harder to study compared with a common germ that regularly circulates, such as the flu.

"That also makes clinical trials in this space super difficult because of the number of people you would have to immunize to protect against one infection," he said. "It's just impractical. " And it means there might not be a large or steady market for a vaccine or treatment, because it would be hard to know who is going to be exposed, and when.

Still, it frustrates researchers and doctors who know there are potential treatments that, with enough sustained investment, could be helping people now.

"What happened was a tragedy, but it can happen not only with this but also other diseases," Tortosa said, referring to the cruise ship outbreak.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

asiaonecom /  🏆 10. in SG

Hantavirus Virus Treatment Vaccine Research

 

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

The show will go on: White House correspondents' dinner rescheduled for July, with Trump attendingThe show will go on: White House correspondents' dinner rescheduled for July, with Trump attendingNEW YORK – And now, Take Two: The White House Correspondents' Association dinner has been rescheduled – with President Donald Trump apparently in attendance.The dinner, cut short in April by a gunman who prosecutors say was trying to assassinate Trump, will now take place on July 24.
Read more »

Singapore Residents Quarantined After Hantavirus Exposure on Cruise ShipSingapore Residents Quarantined After Hantavirus Exposure on Cruise ShipTwo Singapore residents who were aboard the MV Hondius cruise ship continue to test negative for hantavirus and have been allowed to quarantine at home. The individuals, a 67-year-old Singaporean and a 65-year-old Singapore Permanent Resident, were isolated at the National Centre for Infectious Diseases after returning in May as part of a 42-day monitoring period. They were on the same flight as a confirmed hantavirus case who later died. The duo are being monitored daily and will be tested again before release. The Communicable Diseases Agency emphasizes community protection and aligns with latest risk assessment. The World Health Organisation reports eight hantavirus cases globally, including three fatalities. The disease is rodent-borne, transmitted through contact with contaminated rodent excreta, with rare human-to-human transmission of the Andes strain. Symptoms include fever, body aches, fatigue, gastrointestinal issues, and breathing difficulties that can progress to shock and death. The CDA is monitoring the situation and ready to enhance measures if risk increases.
Read more »

Hong Kong actresses Rachel Kan and Christine Ng recount suffering sexual assaults in showbizHong Kong actresses Rachel Kan and Christine Ng recount suffering sexual assaults in showbizShowbiz might be glitzy and glamorous but it has a dark side too.In the June 1 episode of Hong Kong talk show The Wonder Women, actresses Christine Ng and Rachel Kan talked about some predators they encountered in the industry.
Read more »

BTS Singapore Concert Tickets Spark Frenzy with Over 144,000 in Queue for Single ShowBTS Singapore Concert Tickets Spark Frenzy with Over 144,000 in Queue for Single ShowA detailed report on the overwhelming demand for BTS tickets in Singapore, where queues exceeded 144,000 for one show as fans employed advanced strategies and authorities issued scam warnings ahead of the historic four-night concert series.
Read more »



Render Time: 2026-06-04 09:31:13